Myriad's BRCA gene patents ruled invalid by US court
This article was originally published in Scrip
A US federal judge has invalidated some of Myriad Genetics’ patent claims on two key genes involved in hereditary breast and ovarian cancer – BRCA1 and BRCA2 – in a controversial ruling that could have profound effects on gene patent law and the biotech industry's intellectual property foundation if it is upheld on appeal.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.